Completed NA INTERVENTIONAL 2-arm NCT02436005

Dispensing Study for the Phenacite Project

Sponsor: CooperVision, Inc.

Conditions Ametropia

Updated 10 times since 2017 Last updated: Oct 30, 2020 Started: Apr 30, 2015 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02436005, this NA trial focuses on Ametropia and remains completed. Sponsored by CooperVision, Inc., it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

May 2025 — Present [monthly]

Completed NA
Jan 2025 — May 2025 [monthly]

Completed NA
Sep 2024 — Jan 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA

▶ Show 5 earlier versions

Dec 2020 — Jan 2021 [monthly]

Completed NA

Status: Withheld → Completed · Phase: None → NA
Jun 2018 — Dec 2020 [monthly]

Withheld
Apr 2018 — Jun 2018 [monthly]

Withheld

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Withheld NA
Jan 2017 — Feb 2017 [monthly]

Withheld NA

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CooperVision, Inc.

Data source: CooperVision International Limited (CVIL)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bloomington, United States